VYNE Therapeutics’ mission is to improve the lives of patients by developing proprietary, innovative and differentiated therapies in dermatology and beyond.
Location: United States, California, Menlo Park
Employees: 51-200
Total raised: $100M
Founded date: 2003
Investors 5
| Date | Name | Website |
| - | Aisling Ca... | aislingcap... |
| - | F-Prime Ca... | fprimecapi... |
| 14.09.2021 | Vivo Capit... | vivocapita... |
| - | Eight Road... | eightroads... |
| - | Bay City C... | baycitycap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 01.02.2021 | - | $50M | - |
| 18.07.2017 | Series C | $50M | F-Prime Ca... |
Mentions in press and media 14
| Date | Title | Description |
| 01.11.2023 | VYNE Therapeutics Announces Closing of Previously Announced Private Placement of $88.2 Million | - |
| 30.10.2023 | VYNE Therapeutics Announces Private Placement of $88 Million | - |
| 01.02.2021 | VYNE Therapeutics : Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update | BRIDGEWATER - VYNE Therapeutics Inc. (Nasdaq: VYNE) ('VYNE' or the 'Company') today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares of common stock at a purchase price of... |
| 01.02.2021 | VYNE THERAPEUTICS INC. VYNE Therapeutics : Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update | BRIDGEWATER - VYNE Therapeutics Inc. (Nasdaq: VYNE) ('VYNE' or the 'Company') today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares of common stock at a purchase price of... |
| 29.01.2021 | VYNE Therapeutics : Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update | BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares... |
| 29.01.2021 | VYNE THERAPEUTICS INC. VYNE Therapeutics : Announces Closing of $50 Million Registered Direct Offering of Common Stock and Provides Corporate Update | BRIDGEWATER, N.J., Jan. 29, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”) today announced that it has closed its previously announced registered direct offering of an aggregate of 21,097,046 shares... |
| 24.01.2018 | Term Sheet — Wednesday, January 24 | 5 Qs WITH A DEALMAKER Four years ago, Arlan Hamilton was living out of a hotel room that she shared with her mom. At that point, she had given up a career as a live music production coordinator to become a venture capitalist. There were a f... |
| 12.01.2018 | Term Sheet — Friday, January 12 | CUDDLE PUDDLES Good morning, Term Sheet readers. Paid Content Securing the enterprise without boundaries From ExtraHop Last night, Axios reported that one of these parties was held at venture capitalist Steve Jurvetson’s home. The party fol... |
| 18.07.2017 | Menlo Therapeutics Raises $50M in Series C Financing | - |
| 18.07.2017 | F-Prime Capital Joins $50M Series C for Menlo Therapeutics | Menlo Therapeutics Inc. announced today that the company has raised $50M to advance development of serlopitant, a novel NK-1 receptor antagonist, as a once-daily oral treatment for pruritus (itch) associated with atopic dermatitis, psoriasi... |
Show more